Ovarian Carcinoma
Conditions
Keywords
invasion, migration, metastasis, IGFBP-3, transfection, signal transduction.
Brief summary
An ovarian cancer cell line (OVTW-59) derived from an ovarian endometrioid carcinoma was established and its sublines, labeled as P0, P1, P2, P3, and P4 with increasing invasion abilities were selected from transwell invasion chambers.Using cDNA microarray and verified with quantitative reverse-transcriptase polymerase chain reaction, we have identified IGFBP-3 as an invasion-suppressor gene. We plan to study the role of IGFBP-3 in ovarian cancer invasion.
Detailed description
We have successfully established an ovarian cancer cell line (OVTW-59), which was derived from an ovarian endometrioid carcinoma. Its sublines, labeled as P0, P1, P2, P3, and P4 with increasing invasion abilities, were selected from transwell invasion chambers, where P0 represented the original cell line at 100th passage. By using cDNA microarray and verified with quantitative reverse-transcriptase polymerase chain reaction, we have identified the differentially gene expression profiles of these OVTW-59 series cell lines in order to identify the invasion related suppressor and oncogenes from ovarian carcinoma. From these genes, we selected insulin-like growth factor binding protein (IGFBP)-3, which is a suppressor gene, and found it lower expressed in higher-grade tumors and correlated with poor patient survival. In vitro, we found IGFBP-3 related to the inhibition of cancer cell migration. In this study, we plan to setup stable transfected IGFBP-3 cell lines in P0 and P4, and study the relationship among IGFBP-3, metalloproteinase-2 (our previous studies which verified its relationship with tumor invasiveness) and insulin-like growth factor (IGF)-1. We would study the changes in cytoskeletal structures and the known functions of anti-proliferation and apoptosis in IGFBP-3. Furthermore, we would like to investigate the mechanism of IGFBP-3 in the inhibition of invasion/migration of ovarian carcinoma, either signaling through MAPK or PI3K/AKT pathways. Finally, through xenograft, we plan to study for the possible application of IGFBP-3 in ovarian cancer therapy.
Interventions
PROCEDUREimmunohistochemical staining, transfection, invasion assay
Sponsors
National Taiwan University Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
SINGLE
Eligibility
Sex/Gender
FEMALE
Age
21 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Ovarian Endometrioid Adenocarcinoma
Exclusion criteria
Other types of ovaria epithelial cell carcinoma
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| migration, invasion, metastasis | — |
Secondary
| Measure | Time frame |
|---|---|
| transfection efficiency | — |
Countries
Taiwan
Contacts
Primary ContactTorng Pao-Ling, MD, PhD
Outcome results
None listed